NIH Workshop on the Medical Utility of Marijuana
MAPS report(Turning Protests into Protocols: Dr. Harter´s Legacy) to NIDA’s Expert Panel on Medical Marijuana Research – submitted February 25, 1997 following the February 19-20, 1997 …
After Proposition 200 and 215
December 2, 1996 Senate Judiciary Committee Hearing on Medical Marijuana – A message to new visitors of the MAPS website. MAPS Policy in Response to Prop. 200 and Prop. 215
Families Who Value Psychedelics
In this section of the Rites of Passage project, families share their experiences creating their own contexts for psychedelics and marijuana. Just as each family is unique, each of the following accounts …
NIH Grant Application Process
NIH August 1996 Rejection and Critique of "Smoked Marijuana for HIV-Associated Anorexia and Wasting Protocol"
Water Pipe Study
Water Pipe Study by Dale H. Gieringer, Ph.D. (Summer 1996) Why Marijuana Harm Reduction? by Dale H. Gieringer, Ph.D. (Summer 1996)
FY 1996 Financial Report
This past fiscal year, which ran from June 1, 1995 to May 31, 1996, was MAPS' tenth and most successful ever in terms of both fund-raising and membership. I believe that at least part of this increasing …
Human Psychopharmacology of Psilocybin
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …
Smoked Marijuana for HIV-Associated Anorexia and Wasting Protocol
Smoked Marijuana for HIV-Associated Anorexia and Wasting Protocol, (IND#43,542) submitted to the NIH May 1, 1996 by Dr. Donald Abrams.
Psilocybin’s Effects on Cognition
Investigator: Manfred Spitzer, MD, PhD et al. Psychiatrische Universitats Klinic, Heidelberg, Germany Human clinical study, completed and published. More psilocybin research in Germany Spitzer M, et al. …
A Dose/Response Human Pilot Study – Safety and Efficacy of MDMA in Modification of Physical Pain and Psychological Distress in End-Stage Cancer Patients
[This is not the current version of this protocol] Version 4.1 August 22, 1995 A DOSE/RESPONSE HUMAN PILOT STUDY – SAFETY AND EFFICACY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN MODIFICATION OF PHYSICAL …
FY 1995 Financial Report
You can read this report in its original form here. Total Income for FY 94-95 was $107,184. Total Expenses for FY 94-95 were $133,153. See original report.
Human Psychopharmacology of Psilocybin
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …